PierianDx Customer, Moffitt Cancer Center, Launches Clinical NGS Assay, STAR
March 26, 2018
The Moffitt Morsani Molecular Laboratory, located within the Moffitt Cancer Center, announced today that it has launched a new clinical NGS assay, Solid Tumor Actionable Result, or STAR. STAR is based off of the Illumina TruSight Tumor 170 panel that interrogates 170 genes thought to be drivers in the development of solid tumors.
The new assay will enable Moffitt to rapidly assess patient tumors for the presence of mutations to help select treatment with targeted therapies or recruitment into relevant clinical trials.
The Moffitt Morsani Molecular Laboratory collaborated with PierianDx and Illumina to launch STAR.